We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.

Delisted

NAVB was delisted on the 5th of October, 2023.

53 hedge funds and large institutions have $3.91M invested in Navidea Biopharmaceuticals Inc. in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

40% more capital invested

Capital invested by funds: $2.79M → $3.91M (+$1.12M)

2% less funds holding

Funds holding: 5453 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
53
Holders Change
-1
Holders Change %
-1.85%
% of All Funds
1.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
7
Reduced
5
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PP
51
PDS Planning
Ohio
-$8K -1,798 Closed
Ameriprise
52
Ameriprise
Minnesota
-$3K -680 Closed
Deutsche Bank
53
Deutsche Bank
Germany
+$95 +25 New

NAVB Hedge Fund Activity: Q3 2018 in Review

53 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2018, worth a combined $3.91M — up 40% from $2.79M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of NAVB and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.

The largest buyer was Virtu Financial, adding an estimated $12.8K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $81K sold.

  • 53 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2018, down from 54 in Q2 2018.
  • Funds reported $3.91M of Navidea Biopharmaceuticals Inc. stock for Q3 2018, up 40% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2018 and 6 closed out, a net change of -1 holder.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2018 was Virtu Financial, an estimated $12.8K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2018 was Jacobs Levy Equity Management, an estimated $81K sold.

Based on aggregated 13F filings for Q3 2018.